Moderna (NASDAQ:MRNA) Insider Sells $173,550.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Price Performance

MRNA opened at $45.99 on Thursday. The company has a fifty day simple moving average of $49.63 and a 200 day simple moving average of $43.80. The firm has a market cap of $18.25 billion, a price-to-earnings ratio of -5.64 and a beta of 1.05. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $59.55. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. During the same period in the previous year, the business posted ($2.52) earnings per share. Equities research analysts expect that Moderna, Inc. will post -6.51 EPS for the current fiscal year.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lingotto Investment Management LLP raised its holdings in shares of Moderna by 33.7% in the 4th quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after purchasing an additional 125,598 shares in the last quarter. Douglas Lane & Associates LLC raised its holdings in shares of Moderna by 14.4% during the fourth quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock valued at $38,085,000 after acquiring an additional 163,031 shares during the period. Banco Santander S.A. raised its holdings in shares of Moderna by 22.1% during the third quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock valued at $5,577,000 after acquiring an additional 39,056 shares during the period. Sigma Planning Corp acquired a new stake in shares of Moderna during the fourth quarter valued at approximately $907,000. Finally, Gateway Investment Advisers LLC raised its holdings in shares of Moderna by 1,445.1% during the fourth quarter. Gateway Investment Advisers LLC now owns 140,454 shares of the company’s stock valued at $4,142,000 after acquiring an additional 131,364 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MRNA. Sanford C. Bernstein reiterated a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Morgan Stanley set a $33.00 price target on shares of Moderna in a research report on Friday, May 1st. The Goldman Sachs Group boosted their price target on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Royal Bank Of Canada boosted their price target on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research report on Monday, May 4th. Finally, Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $36.60.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.